Nivalis Therapeutics Company Profile (NASDAQ:NVLS)

About Nivalis Therapeutics

Nivalis Therapeutics logoNivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVLS
  • CUSIP:
Key Metrics:
  • Previous Close: $6.31
  • 50 Day Moving Average: $5.24
  • 200 Day Moving Average: $4.69
  • 52-Week Range: $3.68 - $18.59
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.44
  • P/E Growth: 0.00
  • Market Cap: $97.82M
  • Outstanding Shares: 15,503,000
  • Beta: 0.33
Additional Links:
Companies Related to Nivalis Therapeutics:

Analyst Ratings

Consensus Ratings for Nivalis Therapeutics (NASDAQ:NVLS) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.00 (296.20% upside)

Analysts' Ratings History for Nivalis Therapeutics (NASDAQ:NVLS)
Show:
DateFirmActionRatingPrice TargetDetails
8/30/2016Piper Jaffray Cos.Reiterated RatingBuy$16.00View Rating Details
8/8/2016HC WainwrightReiterated RatingBuyView Rating Details
8/1/2016Cowen and CompanyReiterated RatingBuyView Rating Details
10/8/2015Robert W. BairdReiterated RatingPositive$29.00View Rating Details
7/13/2015Stifel NicolausInitiated CoverageBuyView Rating Details
(Data available from 8/31/2014 forward)

Earnings

Earnings History for Nivalis Therapeutics (NASDAQ:NVLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2016        
8/1/2016Q2($0.52)($0.55)ViewN/AView Earnings Details
5/2/2016Q1 16($0.44)($0.51)ViewN/AView Earnings Details
2/29/2016Q4 15($0.36)($0.42)ViewN/AView Earnings Details
11/2/2015Q3 15($0.42)($0.39)ViewN/AView Earnings Details
4/18/2012$0.61$0.61ViewN/AView Earnings Details
2/2/2012$0.47$0.73ViewN/AView Earnings Details
10/26/2011$0.68$0.73ViewN/AView Earnings Details
7/11/2011$0.77$0.79ViewN/AView Earnings Details
4/27/2011$1.03$1.04ViewN/AView Earnings Details
1/31/2011$0.94$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nivalis Therapeutics (NASDAQ:NVLS)
Current Year EPS Consensus Estimate: $-2.29 EPS
Next Year EPS Consensus Estimate: $-2.59 EPS

Dividends

Dividend History for Nivalis Therapeutics (NASDAQ:NVLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nivalis Therapeutics (NASDAQ:NVLS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2016David Malcom RodmanCMOSell5,950$4.66$27,727.00View SEC Filing  
6/16/2016Jon CongletonCEOBuy5,000$3.87$19,350.00View SEC Filing  
3/24/2016Jon CongletonCEOBuy5,000$4.22$21,100.00View SEC Filing  
3/22/2016Jon CongletonCEOBuy5,000$4.38$21,900.00View SEC Filing  
12/11/2015Jon CongletonCEOBuy5,000$8.10$40,500.00View SEC Filing  
12/9/2015Robert E ConwayDirectorBuy10,000$8.10$81,000.00View SEC Filing  
6/23/2015James E FlynnInsiderBuy250,000$14.00$3,500,000.00View SEC Filing  
6/22/2015Bay Master Investors (C HawkesMajor ShareholderBuy17,200$14.69$252,668.00View SEC Filing  
6/18/2015Bay Master Investors (C HawkesMajor ShareholderBuy20,400$14.47$295,188.00View SEC Filing  
6/17/2015Global Healthcare Mas JennisonMajor ShareholderBuy26,149$14.00$366,086.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nivalis Therapeutics (NASDAQ:NVLS)
DateHeadline
finance.yahoo.com logoNivalis (NVLS) Reports Wider-than-Expected Loss in Q2 (NASDAQ:NVLS)
finance.yahoo.com - August 2 at 11:29 AM
News IconNivalis reports $8.5M loss in Q2, continues to work on drug to treat cystic fibrosis (NASDAQ:NVLS)
bizwest.com - August 1 at 6:19 PM
rttnews.com logoEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q2 Earnings Report (NASDAQ:NVLS)
www.rttnews.com - August 1 at 6:19 PM
globenewswire.com logoNivalis Therapeutics Reports Second Quarter 2016 Financial Results (NASDAQ:NVLS)
globenewswire.com - August 1 at 6:19 PM
zacks.com logoNivalis (NVLS): Can the Stock Surprise This Earnings Season? (NASDAQ:NVLS)
www.zacks.com - July 27 at 6:54 PM
nasdaq.com logoNivalis Therapeutics To Present At JMP Securities Conference; Webcast At 1:30PM (NASDAQ:NVLS)
www.nasdaq.com - July 14 at 10:06 AM
News IconNivalis Therapeutics files for $142.5M shelf registration (NASDAQ:NVLS)
bizwest.com - July 8 at 9:30 AM
publicnow.com logoNivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis (NASDAQ:NVLS)
www.publicnow.com - July 7 at 7:11 AM
publicnow.com logoNivalis Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:NVLS)
www.publicnow.com - July 6 at 4:31 PM
publicnow.com logoNivalis Therapeutics to Present at the JMP Securities Life Sciences Conference (NASDAQ:NVLS)
www.publicnow.com - June 15 at 7:19 AM
capitalcube.com logoNivalis Therapeutics, Inc. :NVLS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 (NASDAQ:NVLS)
www.capitalcube.com - June 10 at 5:01 PM
publicnow.com logoNivalis Therapeutics to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:NVLS)
www.publicnow.com - June 1 at 7:23 AM
publicnow.com logoNivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis (NASDAQ:NVLS)
www.publicnow.com - May 16 at 4:22 PM
rttnews.com logoEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q1 Earnings Report (NASDAQ:NVLS)
www.rttnews.com - May 3 at 2:48 PM
sg.finance.yahoo.com logoNivalis Therapeutics reports 1Q loss (NASDAQ:NVLS)
sg.finance.yahoo.com - May 2 at 5:27 PM
publicnow.com logoNivalis Therapeutics Reports First Quarter 2016 Financial Results (NASDAQ:NVLS)
www.publicnow.com - May 2 at 4:20 PM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta (NASDAQ:NVLS)
biz.yahoo.com - April 22 at 4:32 PM
publicnow.com logoNivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:NVLS)
www.publicnow.com - April 22 at 4:16 PM
finance.yahoo.com logoNivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery (NASDAQ:NVLS)
finance.yahoo.com - April 19 at 3:01 PM
feeds.benzinga.com logoNivalis Therapeutics Names David Rodman As Chief Medical Officer (NASDAQ:NVLS)
feeds.benzinga.com - April 18 at 8:22 AM
News IconRecently Changed Price Targets On Nivalis Therapeutics, Inc. (NVLS) (NASDAQ:NVLS)
quadrangleonline.com - April 9 at 2:36 PM
rttnews.com logoThe U.S. Gets 2nd Biosimilar, ORMP Awaits Data This Qtr, PFE Hits Mark In OPAL (NASDAQ:NVLS)
www.rttnews.com - April 6 at 2:47 PM
publicnow.com logoNivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis (NASDAQ:NVLS)
www.publicnow.com - April 5 at 8:20 AM
finance.yahoo.com logoNeed for Patient-Centric Clinical Trials Fuels Adoption of Greenphire's ClinCard Solution (NASDAQ:NVLS)
finance.yahoo.com - April 5 at 8:00 AM
finance.yahoo.com logoNIVALIS THERAPEUTICS, INC. Financials (NASDAQ:NVLS)
finance.yahoo.com - March 12 at 1:04 PM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 10-K, Annual Report (NASDAQ:NVLS)
biz.yahoo.com - March 8 at 5:03 PM
finance.yahoo.com logoNivalis (NVLS) Provides Update on Cystic Fibrosis Candidate (NASDAQ:NVLS)
finance.yahoo.com - March 8 at 4:00 PM
streetinsider.com logoNivalis Therapeutics (NVLS) Expands N91115 Clinical Development Program in CF (NASDAQ:NVLS)
www.streetinsider.com - March 8 at 1:37 PM
finance.yahoo.com logoNivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis (NASDAQ:NVLS)
finance.yahoo.com - March 7 at 4:05 PM
finance.yahoo.com logoNivalis Therapeutics to Present at Two Upcoming Investor Conferences (NASDAQ:NVLS)
finance.yahoo.com - March 2 at 8:00 AM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NASDAQ:NVLS)
biz.yahoo.com - March 1 at 5:48 PM
finance.yahoo.com logoNivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors (NASDAQ:NVLS)
finance.yahoo.com - March 1 at 4:05 PM
rttnews.com logoEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q4 Earnings Report (NASDAQ:NVLS)
www.rttnews.com - March 1 at 1:24 PM
sg.finance.yahoo.com logoNivalis Therapeutics reports 4Q loss (NASDAQ:NVLS)
sg.finance.yahoo.com - February 29 at 7:07 PM
finance.yahoo.com logoNivalis Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results (NASDAQ:NVLS)
finance.yahoo.com - February 29 at 4:05 PM
biz.yahoo.com logoNivalis Therapeutics, Inc. (NVLS) (NASDAQ:NVLS)
biz.yahoo.com - February 20 at 12:52 PM
streetinsider.com logoNivalis Therapeutics (NVLS) Granted FDA Fast Track Status for N91115 in CF (NASDAQ:NVLS)
www.streetinsider.com - February 19 at 1:20 PM
finance.yahoo.com logoApplied Materials, Nivalis & Nordstrom Lead Thursday's After-Hours Movers (NASDAQ:NVLS)
finance.yahoo.com - February 18 at 5:11 PM
finance.yahoo.com logoNivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic Fibrosis (NASDAQ:NVLS)
finance.yahoo.com - February 18 at 4:05 PM
finance.yahoo.com logoWhat Vertex’s Results Mean for Corbus, ProQR, and Nivalis (NASDAQ:NVLS)
finance.yahoo.com - February 16 at 11:36 AM
zacks.com logoWhat's in Store for Nivalis (NVLS) this Earnings Season? (NASDAQ:NVLS)
www.zacks.com - January 29 at 12:50 PM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:NVLS)
biz.yahoo.com - January 26 at 5:02 PM
finance.yahoo.com logoNivalis' N91115 Gets Orphan Drug Status for Cystic Fibrosis (NASDAQ:NVLS)
finance.yahoo.com - January 18 at 2:55 PM
bizjournals.com logoNivalis CF drug gets FDA 'orphan drug' designation; stock rises Friday (NASDAQ:NVLS)
www.bizjournals.com - January 18 at 12:20 PM
finance.yahoo.com logoNivalis Therapeutics (NVLS) Jumps: Stock Moves Up 15.5% (NASDAQ:NVLS)
finance.yahoo.com - January 18 at 8:15 AM
noodls.com logoNivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis (NASDAQ:NVLS)
www.noodls.com - January 15 at 11:25 AM
finance.yahoo.com logo11:17 am Nivalis Therapeutics confirms being granted Orphan Designation by the FDA for N91115 in cystic fibrosis (NASDAQ:NVLS)
finance.yahoo.com - January 15 at 11:17 AM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:NVLS)
biz.yahoo.com - November 3 at 5:04 PM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:NVLS)
biz.yahoo.com - November 2 at 5:03 PM
noodls.com logoNivalis Therapeutics Reports Third Quarter and Nine-Month Financial Results for 2015 (NASDAQ:NVLS)
www.noodls.com - November 2 at 4:26 PM

Social

Nivalis Therapeutics (NASDAQ:NVLS) Chart for Wednesday, August, 31, 2016


Last Updated on 8/31/2016 by MarketBeat.com Staff